Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POLB 001 with teclistamab to prevent severe immune reactions in relapsed or refractory multiple myeloma
ISRCTN50499387Phase 2Recruiting
- Sponsor
- DIDACT Foundation
- Start
- Mar 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 2, open-label trial of POLB 001 and teclistamab in multiple myeloma (MM) (2 arms), sponsored by DIDACT Foundation. Primary endpoints: Incidence of adverse events, Severity of adverse events and 2 more. Started Mar 2026; status: recruiting.
02
Drugs
POLB 001teclistamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ISRCTN50499387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN50499387.